About Us.

The company behind the science.

About Aerpio

Aerpio Therapeutics is a new, clinical-stage biotechnology company focused on the development of novel small molecules and monoclonal antibodies for the treatment of vascular disease and enhancement of wound healing. Aerpio was created in a spin-out transaction from Akebia Therapeutics to enable more rapid development of its exciting compounds.

Aerpio's two lead programs include a Tie-2 activator for diabetic macular edema (DME) and vascular leak, and a Hypoxia-inducible Factor 1-α (HIF1-α) stabilizer for wound healing and the treatment of inflammatory bowel disease. The lead compound for the Tie-2 program, AKB-9778, is currently completing its initial Phase 1 clinical trial, and the HIF1-α stabilization program is progressing toward the clinic with support, in part, from the United States Department of Defense and National Institutes of Health.

The Aerpio team is composed of highly experienced individuals from all facets of pharmaceutical development. During the last 4 years, this team has successfully sharpened their skills at Akebia Therapeutics in the fast paced world of venture backed biopharmaceuticals.

Advisory Board

Name Organization
Randall Johnson, PhD Oxford University
Peter Campochiaro, MD Johns Hopkins School of Medicine
Dietmar Vestweber, PhD Max Planck Institute
Chris Kontos, MD Duke University School of Medicine
Sean Colgan, PhD University of Colorado Denver
Susan Quaggin, MD Northwestern University Feinberg School of Medicine
Robert Shalwitz, MD Akebia Therapeutics, Inc.


Clincal Advisory Board - Ophthalmology

Name Organization
Peter Campochiaro, MD Wilmer Eye Institute, Johns Hopkins School of Medicine
Jeffrey Heier, MD Ophthalmic Consultants of Boston
Tom Gardner, MD Kellogg Eye Institute, University of Michigan
Eugene Ng, MD, MBA Hawaii Retina, Honolulu, HI
Robert Shalwitz, MD Akebia Therapeutics, Inc.

Board Members

Director Campbell Murray, M.D., Novartis Venture Fund
Director Dr. Lauren Silverman, Novartis Venture Fund
Director Muneer Satter, Satter Investment Management LLC
Director Chau Q. Khuong, Private Equity Partner, OrbiMed Healthcare Fund Management
Director Anupam Dalal, M.D., Kearny Venture Partners
Director Paul Weiss, Ph.D., Venture Investors, LLC
Director John Rice, Ph.D., Triathlon Medical Ventures
Director Joseph Gardner, Ph.D., Aerpio Therapeutics, Inc.
Director Duane Nash, M.D., J.D., M.B.A., Vital Therapies, Inc.
Director Adrienne L. Graves, Ph.D., Board Member at the American Society for Cataract & Refractive Surgery Foundation, Glaucoma Research Foundation, Advisory Board Member at The Foundation of the American Academy of Ophthalmology